Financial Data and Key Metrics Changes - In Q1 2025, the company reported net revenue of $20.4 million, with $17.1 million from MyPlifa, $0.1 million from Olpruva, and $2.3 million in net reimbursements from the French EAP for Aramcholamol [29][30] - Operating expenses for Q1 were $22.8 million, a decrease of $0.6 million compared to the same quarter last year [30] - The net loss for Q1 2025 was $3.1 million, compared to a net loss of $16.6 million in the same quarter a year ago [30][31] - Total cash, cash equivalents, and investments as of March 31, 2025, were $68.7 million, a decrease of $6.8 million from December 31, 2024 [30][31] Business Line Data and Key Metrics Changes - MyPlifa's launch has exceeded expectations, with 122 prescription enrollment forms received since launch, indicating that approximately one-third of diagnosed NPC patients in the U.S. have been enrolled [20][21] - Olpruva received a total of 28 prescription enrollment forms since its initial availability, with five forms received in Q1 2025 [12][27] - The company has achieved 38% of covered lives for MyPlifa, which is in line with expectations at this stage of the launch [21][22] Market Data and Key Metrics Changes - The company is focusing on expanding MyPlifa's availability outside the U.S., with plans for a marketing authorization application in Europe in the second half of the year [11] - The European market for NPC is well established, with approximately 1,100 people estimated to be living with the disease [11] Company Strategy and Development Direction - The company is executing on four strategic pillars: commercial excellence, pipeline and innovation, talent and culture, and corporate foundation [5][8] - The focus is on bringing innovative therapies to patients with rare diseases, with a strong emphasis on MyPlifa as a cornerstone treatment for NPC [17][33] - The company is also assessing strategic alternatives for its Phase III ready asset KP1077 for rare sleep disorders [6] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the early success of MyPlifa and the refined marketing strategy for Olpruva, indicating a strong position for future growth [33] - The company believes it is well positioned to support its strategic priorities and execute on its long-term vision, independent from capital markets [31][32] Other Important Information - The company has successfully monetized its Pediatric Rare Disease Priority Review Voucher, adding $148.3 million of non-dilutive capital to its balance sheet [8][31] - The company is committed to patient access and comprehensive patient services through its in-house program, Amplify Assist [27] Q&A Session Summary Question: Details on the number of patients on MyPlifa and reimbursement status - The company received 122 enrollments since launch, with the majority of patients actively on the drug, while some are in the benefits investigation process [36] Question: Reasons for reimbursement denials for MyPlifa - Initial denials are common for rare disease products, primarily due to prior authorization requirements, but the company has been successful in securing coverage through medical exception processes [39][40] Question: Visibility on patient cohorts and enrollment cadence - The company estimates around 600 undiagnosed patients and 300 diagnosed patients, with ongoing efforts to raise awareness and facilitate treatment [47][59] Question: Inventory levels at the end of the quarter - The company is managing inventory closely and maintaining target levels as it supports patient needs during the early launch phase [50] Question: Qualitative metrics on refill rates and patient retention - The majority of patients receiving active drug have continued to refill, reflecting the clinical benefit and durability of MyPlifa [54] Question: Coverage details and impact on patient access - 38% of covered lives have access to MyPlifa, with ongoing efforts to increase this percentage as more plans evaluate the product [63][64]

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $2,810,000, representing a 121% increase year over year compared to $1,270,000 in Q1 2024 [5][21] - Gross margins normalized to 42.4%, compared to 37% in Q4 2024 and 43.6% in Q3 2024 [5][22] - EBITDA loss narrowed to negative $540,000 from negative $840,000 in the same period last year [6][23] - Net loss for Q1 2025 was $710,000, down from a net loss of $850,000 in Q1 2024 [23] Business Line Data and Key Metrics Changes - Contract manufacturing revenue increased by 58% year over year, driven by demand from existing customers and new partnerships [5] - Consumer branded products revenue surged by 189% year over year, significantly boosted by the addition of Silly George [5] - The company expects continued growth in both contract manufacturing and consumer products, with a robust pipeline for 2025 [8][11] Market Data and Key Metrics Changes - The company is seeing increased interest in U.S.-made gels due to potential tariff impacts, which may enhance competitiveness against imported products [19] - There is a growing market for hydrogel applications, particularly in laser hair removal, with significant interest from major companies [42] Company Strategy and Development Direction - The company plans to expand its product lines, including new offerings for MetaGel and Cancoderm, and is transitioning Silly George into a broader beauty brand [12][13] - The partnership with Stata is progressing well, with plans for additional product launches in 2025 and 2026 [14] - The company is strategically managing cash and R&D to ensure high ROI while pursuing growth opportunities [14] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about achieving $13,000,000 in revenue and cash flow positivity in 2025 despite external challenges [20] - The company is monitoring tariff situations closely and is prepared to adjust manufacturing strategies if necessary [16][19] - Management expressed confidence in the growth potential of their products and the overall market, despite uncertainties in the broader economic environment [60] Other Important Information - The company has a cash balance of approximately $1,190,000 as of March 31, 2025 [23] - The company has 7,654,537 shares of common stock outstanding as of May 13, 2025 [23] Q&A Session Summary Question: How much revenue was expected from AbbVie, and does the delay affect guidance? - Management indicated that not much revenue was baked in from AbbVie, so the delay should not significantly impact the $13,000,000 projection [25][26] Question: Can you provide details on the product launch with Stata? - The first product is Histosol, a digestive enzyme, with plans for additional digestive enzymes in the future [30] Question: Is there a seasonal improvement expected for Silly George? - Management expects seasonal growth, especially with new product launches planned for Q3 and Q4 [61][62] Question: Will transitioning manufacturing to Texas impact other business lines? - The company has built a new clean room with enough capacity to accommodate potential shifts in manufacturing [35][36] Question: Will the company survive on current cash reserves until EBITDA positive? - Management believes they can manage with current cash reserves until reaching EBITDA positivity [66]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $12.2 million, down from $15.2 million in Q1 2024, primarily due to a one-time contribution of $3.4 million from the Blue Angels documentary in the previous year [4][16] - Excluding the one-time revenue, core entertainment, publicity, and marketing segment revenue grew by 2% year-over-year to $12.1 million, indicating underlying business strength despite challenges [4][16] - Adjusted operating loss for Q1 2025 was approximately $600,000, comparable to the previous year's adjusted operating income of $1 million when excluding the film revenue [5][17] - Net loss for Q1 2025 was $2.3 million, compared to a net loss of $300,000 in Q1 2024 [17][18] Business Line Data and Key Metrics Changes - The women's sports management firm, Always Alpha, is expected to double its roster of represented athletes and sportscasters by the end of 2025, with plans to expand into women's soccer and basketball [6][8] - The Digital Department launched a dedicated affiliate marketing division, aiming to triple the number of influencers on its roster by the end of the year [9][30] - The core entertainment, publicity, and marketing segment demonstrated resilience with a 2% revenue increase despite external challenges [16][60] Market Data and Key Metrics Changes - The affiliate marketing sector is estimated to be over $17 billion globally, and the company aims to capture a significant share of this market through its new division [9][30] - The company is positioned as a comprehensive agency in the women's sports space, enhancing its competitive edge in a rapidly growing market [6][34] Company Strategy and Development Direction - The company is focusing on strategic investments in women's sports and affiliate marketing to broaden its addressable market and create sustainable growth opportunities [14][54] - Plans to increase the frequency of film productions and expand ventures are also part of the growth strategy, with a focus on long-term success [55][66] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the impact of the LA wildfires on Q1 performance but expressed confidence in returning to normal operations in Q2 and beyond [58][60] - The company remains optimistic about achieving stronger growth in 2025, with no loss of confidence in its business trajectory [58][61] Other Important Information - The company was named Agency of the Year by Observer's 2025 PR Power List, validating its strategy and talent depth [13] - The film "Youngblood" is targeting a February 2026 release, coinciding with the Winter Olympics, which is expected to enhance its marketability [50][51] Q&A Session Summary Question: Growth strategy for Always Alpha and revenue potential - Management discussed the need for more managers to support the growth of Always Alpha and the expected timeline for revenue recognition from new talent [20][22][26] Question: Affiliate marketing growth and strategy - Management explained the strategy for expanding the affiliate marketing division, emphasizing the potential for quick revenue generation and the importance of training affiliate managers [29][30][32] Question: Financial outlook and impact of past events - Management reiterated confidence in the company's growth trajectory despite past challenges, highlighting the resilience shown in Q1 revenue performance [57][60]

Semler Scientific (SMLR) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Speaker0 Good afternoon, and welcome to the Semler Scientific First Quarter twenty twenty five Financial Results Conference Call. All participants will be in a listen only mode. After today's prepared remarks, as time permits, management will take questions submitted prior to this call via email. Please note this event is being recorded. Before we begin, Seminole Scientific needs to remind you that certain comments made during this call ...

Genasys (GNSS) Q2 2025 Earnings Call May 13, 2025 04:30 PM ET Speaker0 At this time, it is my pleasure to turn the floor over to your host, Brian Alger, SVP, Investor Relations and Corporate Development. Welcome, Brian. The floor is yours. Speaker1 Good afternoon. Welcome to Genesis' fiscal twenty twenty five second quarter results conference call. I'm Brian Alger, SVP, Investor Relations and Corporate Development for Genesis. With me on the call today are Richard Danforth, our CEO and Dennis Kwan, the comp ...

HYLIION® 2025 | Proprietary 2 2025 1st quarter Earnings call May 14th, 2025 DISCLAIMER The information in this presentation includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of present or historical fact included in this presentation, regarding Hyliion and its future financial and operational performance, as well as its strategy, future op ...

ASM: TSX/NYSE American www.avino.com A Clear Path to Transformational Growth May 2025 A CLEAR PATH TO TRANSFORMATIONAL GROWTH The Avino Mine Property ASM: TSX/NYSE American www.avino.com A Clear Path to Transformational Growth 2 CAUTIONARY DISCLAIMER: FORWARD-LOOKING STATEMENTS This presentation contains "forward-looking information" and "forward-looking statements" (together, the "forward looking statements") within the meaning of applicable securities laws and the United States Private Securities Litigati ...

Company Update 1Q 2025 1 1 Forward-looking statements ABOUT THIS PRESENTATION This presentation is provided by Oklo Inc. ("Oklo") for informational purposes only. The information contained herein does not purport to be all inclusive and no representations or warranties, express or implied, are given in, or in respect of, this presentation. To the fullest extent permitted by law, in no circumstances will Oklo or any of its subsidiaries, interest holders, affiliates, representatives, partners, directors, offi ...

INVESTOR PRESENTATION Q1 2025 INVESTOR PRESENTATION INVESTOR PRESENTATION Q1 2025 Q1 2025 1 NOTES REGARDING THIS PRESENTATION This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements relating to the expected performance of our business, future financial results, strategy, long-term growth and overa ...

Corporate Presentation May 2025 Forward-Looking Statements Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Act of 1995, known as the PSLRA. These include statements regarding management's intention, plans, beliefs, expectations or forecasts for the future, and, therefore, you are cautioned not to plac ...